Survival with newly diagnosed metastatic prostate cancer in the "Docetaxel Era": Data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019).
Authors
James, NSpears, M
Clarke, Noel W
Dearnaley, D
De Bono, J
Gale, J
Hetherington, J
Hoskin, P
Jones, R
Laing, R
Lester, J
McLaren, D
Parker, C
Parmar, M
Ritchie, A
Russell, J
Strebel, R
Thalmann, G
Mason, M
Sydes, M
Affiliation
University of Warwick, Coventry, UK.Issue Date
2014-10-06
Metadata
Show full item recordAbstract
Prostate cancer (PCa) is the second most common disease among men worldwide. It is important to know survival outcomes and prognostic factors for this disease. Recruitment for the largest therapeutic randomised controlled trial in PCa-the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial (STAMPEDE)-includes men with newly diagnosed metastatic PCa who are commencing long-term androgen deprivation therapy (ADT); the control arm provides valuable data for a prospective cohort.Citation
Survival with newly diagnosed metastatic prostate cancer in the "Docetaxel Era": Data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019). 2014: Eur UrolJournal
European UrologyDOI
10.1016/j.eururo.2014.09.032PubMed ID
25301760Type
ArticleLanguage
enISSN
1873-7560ae974a485f413a2113503eed53cd6c53
10.1016/j.eururo.2014.09.032